Study looks at impact of socioeconomic status on dementia risk
"If you look at all the things we know that may be associated with the risk of developing dementia, the two strongest are age ...
Le Lézard23h
Update on regulatory review of lecanemab for treatment of early Alzheimer's disease in the European Union
BioArctic AB's (publ) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two additional questions. These ...